New study examines migraine drug Rimegepant's safety in pregnancy
NCT ID NCT05198245
First seen Nov 01, 2025 · Last updated May 19, 2026 · Updated 30 times
Summary
This study aims to understand the risks of birth defects, miscarriage, stillbirth, and low birth weight in pregnant women with migraine who took the drug rimegepant. Researchers will compare these outcomes to similar women who did not take the drug. The study is observational, meaning no treatment is given—it simply looks back at existing medical records.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIGRAINE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Pfizer
New York, New York, 10001, United States
Conditions
Explore the condition pages connected to this study.